AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18049345 — intervention group
Group type: COMPARATOR
Intervention: QI-Meds
Number of subjects: 1188
Study 16288704 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/d orally for 1 month)
Number of subjects: 0
Study 16288704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12126818 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation combined with immediate androgen suppression (Goserelin 3.6 mg subcutaneously every 4 weeks for 3 years, and Cyproterone acetate 150 mg orally for 1 month starting 1 week before goserelin)
Number of subjects: 415
Study 12126818 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (50 Gy radiation delivered to the pelvis over 5 weeks, and 20 Gy over 2 weeks as a prostatic boost)
Number of subjects: 415
Study 10402684 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious-ambivalent attachment style
Number of subjects: 3
Study 10402684 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant attachment style
Number of subjects: 3
Study 7487847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) without explicit exposure instructions
Number of subjects: 0
Study 7487847 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention treatment without cognitive restructuring procedures
Number of subjects: 0
Study 2154431 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2 to 5)
Number of subjects: 101
Study 2154431 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg qid for ten days)
Number of subjects: 101
Study 31358533 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley Recombinant Inbred Diverse Germplasm Population (BRIDG6)
Number of subjects: 6160
Study 31358533 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype-based analysis of HvPpd-H1
Number of subjects: 6160
Study 31358533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsampling strategies for QTL detection
Number of subjects: 6160
Study 28087371 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 133
Study 28087371 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 133
Study 28087371 — intervention group
Group type: COMPARATOR
Intervention: cTnI
Number of subjects: 133
Study 26094950 — intervention group
Group type: EXPERIMENTAL
Intervention: Full serving of rice
Number of subjects: 39
Study 26094950 — intervention group
Group type: COMPARATOR
Intervention: Half serving of rice
Number of subjects: 39
Study 23819612 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic adsorbent (modified zeolite)
Number of subjects: 0
Study 23819612 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic adsorbent (esterified glucomannans)
Number of subjects: 0
Study 23819612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed adsorbent (inorganic and organic components plus enzymes)
Number of subjects: 0
Study 22075527 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthware intervention
Number of subjects: 3283
Study 22075527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3283
Study 19240996 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT)
Number of subjects: 170
Study 19240996 — intervention group
Group type: EXPERIMENTAL
Intervention: NHT and adjuvant hormonal therapy (HT)
Number of subjects: 170
Study 19240996 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 170
Study 19240996 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term NHT
Number of subjects: 170
Study 17302021 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 0
Study 17302021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17302021 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT
Number of subjects: 0
Study 14720160 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal approach
Number of subjects: 20
Study 14720160 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 20
Study 14720160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 20
Study 11172836 — intervention group
Group type: COMPARATOR
Intervention: Progesterone 600 mg/d for 3 weeks after a positive hCG result (Control)
Number of subjects: 400
Study 11172836 — intervention group
Group type: EXPERIMENTAL
Intervention: No progesterone supplementation (Intervention)
Number of subjects: 400
Study 10461102 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroventral pallidotomy
Number of subjects: 33
Study 10461102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrolateral thalamotomy
Number of subjects: 33
Study 8168773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with a history of substance abuse
Number of subjects: 225
Study 8168773 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without a history of substance abuse
Number of subjects: 225
Study 3202502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (A)
Number of subjects: 8
Study 3202502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (S)
Number of subjects: 8
Study 3202502 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (S) added to aminophylline (A)
Number of subjects: 8
Study 3202502 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (A) added to salbutamol (S)
Number of subjects: 8
Study 3202502 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 8
Study 3202502 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (A)
Number of subjects: 8
Study 27573207 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 16
Study 28325148 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (500 mg twice daily for 12 weeks)
Number of subjects: 40
Study 28325148 — intervention group
Group type: COMPARATOR
Intervention: Control (no M2000 treatment)
Number of subjects: 40
Study 26122282 — intervention group
Group type: EXPERIMENTAL
Intervention: DP+R method (digital photographs plus recall)
Number of subjects: 91
Study 26122282 — intervention group
Group type: COMPARATOR
Intervention: TDEE(DLW) (total daily energy expenditure assessed by doubly labeled water)
Number of subjects: 91
Study 26122282 — intervention group
Group type: EXPERIMENTAL
Intervention: DP+R method
Number of subjects: 91
Study 23683069 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 20
Study 23683069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20496981 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus self-regulation
Number of subjects: 255
Study 20496981 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 255
Study 18828814 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged implants (ITI)
Number of subjects: 31
Study 18828814 — intervention group
Group type: COMPARATOR
Intervention: Submerged implants (3i)
Number of subjects: 31
Study 16573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg once daily via Turbuhaler
Number of subjects: 1981
Study 16573704 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily via Turbuhaler
Number of subjects: 1981
Study 14698701 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 75
Study 14698701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 75
Study 14698701 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 75
Study 14698701 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 11108748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0
Study 11108748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8805890 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat challenge (overheating)
Number of subjects: 8
Study 8805890 — intervention group
Group type: COMPARATOR
Intervention: Control (non-susceptible piglets)
Number of subjects: 8
Study 1381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 0
Study 1381164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6396969 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg piridoxilate
Number of subjects: 10
Study 6396969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6396969 — intervention group
Group type: COMPARATOR
Intervention: Traffic noise (placebo)
Number of subjects: 10
Study 6396969 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg piridoxilate (with traffic noise)
Number of subjects: 10
Study 31985066 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + adjunct probiotic therapy (PT) in non-chewers (group 4)
Number of subjects: 126
Study 31985066 — intervention group
Group type: COMPARATOR
Intervention: SRP alone in non-chewers (group 3)
Number of subjects: 126
Study 31985066 — intervention group
Group type: COMPARATOR
Intervention: SRP alone in shamma users (group 1)
Number of subjects: 126
Study 31985066 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + adjunct probiotic therapy (PT) in shamma users (group 2)
Number of subjects: 126
Study 30577220 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Transplantation (RTx)
Number of subjects: 84
Study 30577220 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 84
Study 26197241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 2183
Study 26197241 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedure
Number of subjects: 2183
Study 24818626 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 85
Study 24818626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 85
Study 22399084 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5g arginine
Number of subjects: 23
Study 22399084 — intervention group
Group type: EXPERIMENTAL
Intervention: 9g arginine
Number of subjects: 23
Study 22399084 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified dosage)
Number of subjects: 23
Study 22399084 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished patients
Number of subjects: 23
Study 20391240 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating television programmes
Number of subjects: 6
Study 18597808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task with varying presentation times (100, 200, 400, 800 ms) and background slant (0 degrees or 60 degrees)
Number of subjects: 0
Study 18597808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task with contextual information learned across trials
Number of subjects: 0
Study 18597808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task with presentation times less than 100 ms
Number of subjects: 0
Study 31319908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 650
Study 12514150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg x kg(‐1) tramadol
Number of subjects: 60
Study 12514150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg x kg(‐1) tramadol
Number of subjects: 60
Study 12514150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg x kg(‐1) tramadol
Number of subjects: 60
Study 12514150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg x kg(‐1) tramadol
Number of subjects: 60
Study 12514150 — intervention group
Group type: COMPARATOR
Intervention: Control (Groups II-IV)
Number of subjects: 60
Study 10225072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Nerve Stimulation (MNS)
Number of subjects: 101
Study 10225072 — intervention group
Group type: COMPARATOR
Intervention: Transarterial (TA)
Number of subjects: 101
Study 8544795 — intervention group
Group type: COMPARATOR
Intervention: Regimen C (Vincristine + Actinomycin D)
Number of subjects: 0
Study 8544795 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D (Vincristine + Actinomycin D + Doxorubicin)
Number of subjects: 0
Study 8544795 — intervention group
Group type: COMPARATOR
Intervention: Regimen DD-RT (Vincristine + Actinomycin D + Cyclophosphamide + Whole Lung Radiation Therapy)
Number of subjects: 0
Study 8544795 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen J (Vincristine + Actinomycin D + Doxorubicin + Whole Lung Radiation Therapy)
Number of subjects: 0
Study 1830551 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10, 20, or 40 mg day‐1)
Number of subjects: 225
Study 1830551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 6361990 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 100
Study 6361990 — intervention group
Group type: COMPARATOR
Intervention: Pre-immune serum (control)
Number of subjects: 100
Study 31138168 — intervention group
Group type: EXPERIMENTAL
Intervention: Povu Poa intervention (new handwashing station dispensing foaming soap and rinse water, combined with behavior change promotion)
Number of subjects: 30
Study 31138168 — intervention group
Group type: EXPERIMENTAL
Intervention: Povu Poa intervention
Number of subjects: 30
Study 31138168 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools that had not yet received the intervention)
Number of subjects: 30
Study 28102978 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode psychosis (FEP) patients
Number of subjects: 113
Study 28102978 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive patients
Number of subjects: 113
Study 28102978 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 113
Study 28102978 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of type 2 diabetes mellitus
Number of subjects: 113
Study 28102978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 113
Study 26138109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosal graft urethroplasty
Number of subjects: 80
Study 26138109 — intervention group
Group type: COMPARATOR
Intervention: Ventral onlay buccal mucosal graft urethroplasty
Number of subjects: 80
Study 23278292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociological investigations into the social construction of diseases, surveillance systems, public health governance, and public/media responses
Number of subjects: 0
Study 21883004 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 13
Study 18974700 — intervention group
Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG) assessment of venous filling index (VFI)
Number of subjects: 135
Study 18974700 — intervention group
Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG) assessment of venous volume, ejection fraction, and residual volume fraction
Number of subjects: 135
Study 17065871 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course to improve communication skills (small-group teaching with lecture, discussion, and role-play)
Number of subjects: 56
Study 17065871 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course to improve communication skills
Number of subjects: 56
Study 17065871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 12927634 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect induced by exposure to three brief shocks
Number of subjects: 127
Study 12927634 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect elicited by the threat of shock without presentation
Number of subjects: 127
Study 12927634 — intervention group
Group type: COMPARATOR
Intervention: Neutral affect, with no intervention
Number of subjects: 127
Study 11370546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold shower (n = 8)
Number of subjects: 16
Study 11370546 — intervention group
Group type: COMPARATOR
Intervention: Without cold shower (n = 8)
Number of subjects: 16
Study 9403542 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CVC (antibiotic- and antiseptic-coated central venous catheter)
Number of subjects: 282
Study 9403542 — intervention group
Group type: COMPARATOR
Intervention: S‐CVC (standard central venous catheter)
Number of subjects: 282
Study 8218755 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride q.d.s.
Number of subjects: 155
Study 8218755 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cisapride b.d.
Number of subjects: 155
Study 8218755 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 155
Study 8218755 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reflux symptom score
Number of subjects: 155
Study 3034107 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate/fentanyl (n = 12)
Number of subjects: 29
Study 3034107 — intervention group
Group type: COMPARATOR
Intervention: Methohexital/fentanyl (n = 9)
Number of subjects: 29
Study 3034107 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/fentanyl (n = 8)
Number of subjects: 29
Study 31674134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg intravitreal ranibizumab injection
Number of subjects: 24
Study 31674134 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival saline injection (placebo)
Number of subjects: 24
Study 29944646 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-sex HIV self-testing (HIVST)
Number of subjects: 400
Study 29944646 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous HIV self-testing experiences
Number of subjects: 400
Study 27965209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride combination pill
Number of subjects: 730
Study 27965209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 24090282 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 301
Study 24090282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 301
Study 24090282 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 301
Study 22763268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quark RMR
Number of subjects: 24
Study 22763268 — intervention group
Group type: COMPARATOR
Intervention: Deltatrac
Number of subjects: 24
Study 22763268 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM Express
Number of subjects: 24
Study 21587082 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 149
Study 21587082 — intervention group
Group type: COMPARATOR
Intervention: Invasive mediastinal staging (mediastinoscopy alone or combined with thoracotomy)
Number of subjects: 149
Study 17479312 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal bipolar vessel sealing (EBVS) device (group A)
Number of subjects: 50
Study 17479312 — intervention group
Group type: COMPARATOR
Intervention: UltraSonic Shears (USS) device (group B)
Number of subjects: 50
Study 16870915 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical management and once-weekly medication dispensing
Number of subjects: 166
Study 16870915 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical management and thrice-weekly medication dispensing
Number of subjects: 166
Study 16870915 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced medical management and thrice-weekly medication dispensing
Number of subjects: 166
Study 16870915 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 166
Study 14566214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buspirone patches
Number of subjects: 64
Study 14566214 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 64
Study 10928726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation‐Oriented Cue Exposure (MOCE)
Number of subjects: 91
Study 10928726 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Self‐Control Training (BSCT)
Number of subjects: 91
Study 10928726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of alcohol consumption and problems
Number of subjects: 91
Study 8769938 — intervention group
Group type: EXPERIMENTAL
Intervention: GTPN (TPN containing 0.23 g glutamine/kg.day)
Number of subjects: 20
Study 8769938 — intervention group
Group type: COMPARATOR
Intervention: CTPN (standard TPN)
Number of subjects: 20
Study 8769938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 8769938 — intervention group
Group type: EXPERIMENTAL
Intervention: GTPN
Number of subjects: 20
Study 1430300 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR 120 mg
Number of subjects: 275
Study 1430300 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR 240 mg
Number of subjects: 275
Study 1430300 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR 360 mg
Number of subjects: 275
Study 1430300 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem SR 480 mg
Number of subjects: 275
Study 1430300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 275
Study 3950055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam tablet in the morning (7 AM)
Number of subjects: 10
Study 3950055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam tablet in the evening (10 PM)
Number of subjects: 10
Study 30073795 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/carboplatin (control arm)
Number of subjects: 455
Study 26683790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg)
Number of subjects: 96
Study 26683790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24806623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoenteric tube
Number of subjects: 42
Study 24806623 — intervention group
Group type: COMPARATOR
Intervention: Jejunostomy
Number of subjects: 42
Study 23115765 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group (primary closure with drain application)
Number of subjects: 20
Study 23115765 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure group (open healing)
Number of subjects: 20
Study 19912243 — intervention group
Group type: COMPARATOR
Intervention: MMI 30 mg
Number of subjects: 134